AR121913A1 - Compuestos terapéuticos - Google Patents
Compuestos terapéuticosInfo
- Publication number
- AR121913A1 AR121913A1 ARP210101081A ARP210101081A AR121913A1 AR 121913 A1 AR121913 A1 AR 121913A1 AR P210101081 A ARP210101081 A AR P210101081A AR P210101081 A ARP210101081 A AR P210101081A AR 121913 A1 AR121913 A1 AR 121913A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- heteroaryl
- alkoxy
- optionally substituted
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 230000001225 therapeutic effect Effects 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 26
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 19
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 16
- 125000001072 heteroaryl group Chemical group 0.000 abstract 15
- 125000001424 substituent group Chemical group 0.000 abstract 14
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 13
- 125000005843 halogen group Chemical group 0.000 abstract 13
- 125000000623 heterocyclic group Chemical group 0.000 abstract 13
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 abstract 11
- 125000003118 aryl group Chemical group 0.000 abstract 11
- 239000001257 hydrogen Substances 0.000 abstract 10
- 229910052739 hydrogen Inorganic materials 0.000 abstract 10
- 150000002431 hydrogen Chemical group 0.000 abstract 7
- 229910052757 nitrogen Inorganic materials 0.000 abstract 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- -1 C1−4-R30-alkylene Chemical group 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 abstract 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 229910052717 sulfur Chemical group 0.000 abstract 2
- 239000011593 sulfur Chemical group 0.000 abstract 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 1
- 125000001627 3 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000001963 4 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 abstract 1
- RIXDCMAKTPXKHE-MNUVWUGUSA-N C[C@](CCCC1)([C@@H]1C(N(CCC1=C(C=C2)Cl)[C@H](CN(CCC3)C3=O)C1=C2OCC1=C(C(F)F)N(C)N=N1)=O)C(N)=O Chemical compound C[C@](CCCC1)([C@@H]1C(N(CCC1=C(C=C2)Cl)[C@H](CN(CCC3)C3=O)C1=C2OCC1=C(C(F)F)N(C)N=N1)=O)C(N)=O RIXDCMAKTPXKHE-MNUVWUGUSA-N 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 239000012190 activator Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000001246 bromo group Chemical group Br* 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2005852.5A GB202005852D0 (en) | 2020-04-22 | 2020-04-22 | Therapeutic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR121913A1 true AR121913A1 (es) | 2022-07-20 |
Family
ID=70859963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210101081A AR121913A1 (es) | 2020-04-22 | 2021-04-22 | Compuestos terapéuticos |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230159511A1 (https=) |
| EP (1) | EP4139295B1 (https=) |
| JP (1) | JP7751165B2 (https=) |
| KR (1) | KR20230004722A (https=) |
| CN (1) | CN115667242B (https=) |
| AR (1) | AR121913A1 (https=) |
| AU (1) | AU2021258539A1 (https=) |
| BR (1) | BR112022021370A2 (https=) |
| CA (1) | CA3174360A1 (https=) |
| ES (1) | ES3031970T3 (https=) |
| GB (1) | GB202005852D0 (https=) |
| IL (1) | IL297440A (https=) |
| MX (1) | MX2022013396A (https=) |
| PH (1) | PH12022552773A1 (https=) |
| WO (1) | WO2021214472A1 (https=) |
| ZA (1) | ZA202211464B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021004566A (es) | 2018-10-22 | 2021-06-08 | C4X Discovery Ltd | Compuestos terapeuticos. |
| US20240424112A1 (en) | 2021-10-25 | 2024-12-26 | C4X Discovery Limited | Tetrahydroisoquinoline compounds that are keap1 binders. |
| PE20241779A1 (es) * | 2022-01-07 | 2024-09-03 | Chugai Pharmaceutical Co Ltd | Compuesto heterociclico que contiene nitrogeno que tiene un efecto de activacion del nrf2 |
| WO2024130411A1 (en) * | 2022-12-21 | 2024-06-27 | Variational Ai Inc. | Protease inhibitors and methods of using same |
| WO2024262491A1 (ja) * | 2023-06-19 | 2024-12-26 | 中外製薬株式会社 | Ｎｒｆ２活性化作用を有する含窒素複素環化合物の結晶 |
| EP4596534A1 (en) * | 2024-01-31 | 2025-08-06 | University of Copenhagen | Noncovalent small-molecule inhibitors of the keap1-nrf2 interaction |
| WO2025237912A1 (en) | 2024-05-13 | 2025-11-20 | Astrazeneca Ab | Keap1 inhibitors for use in the treatment of bronchiectasis |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140256767A1 (en) * | 2011-10-31 | 2014-09-11 | The Broad Institute, Inc. | Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators |
| CA2988373A1 (en) * | 2015-06-15 | 2016-12-22 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulators |
| JP2020097526A (ja) * | 2017-03-28 | 2020-06-25 | 武田薬品工業株式会社 | 複素環化合物 |
| MX2021004566A (es) | 2018-10-22 | 2021-06-08 | C4X Discovery Ltd | Compuestos terapeuticos. |
-
2020
- 2020-04-22 GB GBGB2005852.5A patent/GB202005852D0/en not_active Ceased
-
2021
- 2021-04-22 BR BR112022021370A patent/BR112022021370A2/pt unknown
- 2021-04-22 ES ES21724005T patent/ES3031970T3/es active Active
- 2021-04-22 KR KR1020227040564A patent/KR20230004722A/ko active Pending
- 2021-04-22 US US17/920,244 patent/US20230159511A1/en active Pending
- 2021-04-22 JP JP2022564532A patent/JP7751165B2/ja active Active
- 2021-04-22 MX MX2022013396A patent/MX2022013396A/es unknown
- 2021-04-22 WO PCT/GB2021/050975 patent/WO2021214472A1/en not_active Ceased
- 2021-04-22 AR ARP210101081A patent/AR121913A1/es unknown
- 2021-04-22 PH PH1/2022/552773A patent/PH12022552773A1/en unknown
- 2021-04-22 AU AU2021258539A patent/AU2021258539A1/en active Pending
- 2021-04-22 CA CA3174360A patent/CA3174360A1/en active Pending
- 2021-04-22 CN CN202180030434.4A patent/CN115667242B/zh active Active
- 2021-04-22 IL IL297440A patent/IL297440A/en unknown
- 2021-04-22 EP EP21724005.0A patent/EP4139295B1/en active Active
-
2022
- 2022-10-19 ZA ZA2022/11464A patent/ZA202211464B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES3031970T3 (en) | 2025-07-14 |
| EP4139295B1 (en) | 2025-04-09 |
| JP2023524207A (ja) | 2023-06-09 |
| ZA202211464B (en) | 2025-05-28 |
| AU2021258539A1 (en) | 2022-11-10 |
| GB202005852D0 (en) | 2020-06-03 |
| IL297440A (en) | 2022-12-01 |
| WO2021214472A1 (en) | 2021-10-28 |
| MX2022013396A (es) | 2022-12-13 |
| KR20230004722A (ko) | 2023-01-06 |
| JP7751165B2 (ja) | 2025-10-08 |
| EP4139295A1 (en) | 2023-03-01 |
| US20230159511A1 (en) | 2023-05-25 |
| CA3174360A1 (en) | 2021-10-28 |
| PH12022552773A1 (en) | 2024-03-25 |
| CN115667242A (zh) | 2023-01-31 |
| BR112022021370A2 (pt) | 2022-12-06 |
| CN115667242B (zh) | 2025-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR121913A1 (es) | Compuestos terapéuticos | |
| AR111776A1 (es) | Heteroarilos inhibidores de las proteínas ras mutantes de g12c | |
| AR096643A1 (es) | Procedimiento de síntesis para la preparación de análogos macrocíclicos c1-ceto de halicondrina b e intermediarios útiles en la misma incluyendo intermediarios que contienen grupos -so₂-(p-tolilo) | |
| AR091368A1 (es) | Compuestos y composiciones para modular la actividad de egfr | |
| AR100438A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
| AR114083A2 (es) | AGENTES INDUCTORES DE APOPTOSIS CON SELECTIVIDAD POR Bcl-2 PARA EL TRATAMIENTO DE CÁNCER Y ENFERMEDADES INMUNES | |
| AR097633A1 (es) | Pesticidas de azol bicíclico sustituido con heterociclos | |
| AR055630A1 (es) | Derivados de diazaspiro como antagonistas del receptor ccr8, un proceso para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades respiratorias. | |
| AR110139A1 (es) | COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV | |
| AR091261A1 (es) | Derivados de alcoholes 1-fenil-2-piridinilalquilicos como inhibidores de la fosfodiesterasa | |
| AR104259A1 (es) | Inhibidores de bromodominio | |
| AR113886A1 (es) | Derivados de indol macrocíclicos | |
| AR099936A1 (es) | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados | |
| AR093413A2 (es) | Antagonistas de neuroquinina, composiciones farmaceuticas que los comprenden, y uso de dichos antagonistas en la preparacion de un medicamento | |
| AR088989A1 (es) | Derivados biciclicos de dihidroisoquinolin-1-ona | |
| AR110227A2 (es) | Derivados de pirazol con acción sobre fgf | |
| AR088014A1 (es) | Derivados de alcoholes 1-fenil-2-piridinil alquilicos como inhibidores de la fosfodiesterasa | |
| AR091464A1 (es) | Compuestos biciclicos de tiofenilamida | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR113888A1 (es) | Derivados de indol macrocíclicos sustituidos | |
| CO2020001326A2 (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
| AR117037A1 (es) | Compuestos pirazol para el tratamiento de enfermedades autoinmunitarias | |
| AR097754A1 (es) | Derivados sustituidos de fenilalanina | |
| AR115898A1 (es) | 1,7-naftiridinas como inhibidores de cdk8/19 | |
| AR087577A1 (es) | Derivados de furo[3,4-c]quinolina, medicamentos que contienen dichos compuestos, su uso y proceso para su preparacion |